← All trials
NCT00006164
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2000
- Primary completion
- Apr 1, 2007
- Completion date
- Oct 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 1050
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- St. Louis UniversityOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Medical College of VirginiaOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- University of Southern CaliforniaOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Cancer Institute (NCI)Collaborator
- RocheCollaborator
- National Institutes of Health (NIH)Overall official - principal investigator
- National Institutes of Health (NIH)Collaborator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.